HHS approves 340B rebate model plans for Merck, Bristol Myers and othersnews2025-10-30T19:47:44+00:00October 30th, 2025|Endpoints News|
Lilly CEO expects more ‘noise’ as Metsera M&A fight beginsnews2025-10-30T19:32:53+00:00October 30th, 2025|Endpoints News|
Merck CEO touts Winrevair launch, says he’s looking for deals ‘with urgency’news2025-10-30T18:49:30+00:00October 30th, 2025|Endpoints News|
Post-Hoc Live: Breaking down the M&A drama between Pfizer, Metsera and Novonews2025-10-30T17:06:04+00:00October 30th, 2025|Endpoints News|
National Resilience secures $825M in funding; Regeneron details US manufacturing plansnews2025-10-30T15:34:59+00:00October 30th, 2025|Endpoints News|
Bristol Myers Q3 earnings: Cobenfy anxiety, PD-1xVEGF strategy and MFNnews2025-10-30T15:34:04+00:00October 30th, 2025|Endpoints News|
The showdown over Metsera: Pfizer and Novo prepare for a bidding warnews2025-10-30T15:20:13+00:00October 30th, 2025|Endpoints News|
Tectonic shares rise on back of Phase 1 heart failure datanews2025-10-30T15:18:52+00:00October 30th, 2025|Endpoints News|
Novo Nordisk’s new CEO is chasing the deals its former leaders wouldn’tnews2025-10-30T15:12:24+00:00October 30th, 2025|Endpoints News|
Evommune plans to raise about $150M in IPO for inflammatory diseasesnews2025-10-30T14:27:55+00:00October 30th, 2025|Endpoints News|
